Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis

Cheng, Jackie Y. W., Chen, Ronald Y. L., Ko, John S. N., Ng, Emil M. L. · 2007 · Psychopharmacology

Abstract

Objectives The objective of this study was to evaluate the efficacy and safety of atomoxetine in children and adolescents. Materials and methods We searched for studies published between 1985 and 2006 through Medline, PubMed, PsychInfo and Cochrane Central Register of Controlled Trials (CENTRAL 2006 Issue 3) using keywords related to atomoxetine and attention-deficit/hyperactivity disorder (ADHD) and scanned though reference lists. We included nine randomized placebo-controlled trials (atomoxetine:placebo = 1,150:678). Results Atomoxetine was superior (p Conclusions Atomoxetine is efficacious in reducing ADHD symptoms. It may have a role in treating comorbid ODD or depression, and probably in comorbid anxiety.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00213-007-0840-x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Research works printed but not linked: 3

  1. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD rating scale-IV: checklists, norms, and cinical interpretations. Guilford, New York
  2. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 1st edn. The Health Institute, New England Medical Center, Boston
  3. Tannock R, Schachar R (1992) Is ADHD with comorbid overanxious disorder different from ADHD? In: Comorbidity of ADHD: discriminating features and methodologic problems, Newcorn J (chair). Symposium conducted at the 39th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC

Cited by

See all 190

Metadata

Authors
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L.
Affiliations
Queen Mary Hospital (CN)
Corresponding author
Cheng, Jackie Y. W.
Venue
Psychopharmacology
Published
2007-06-16
Volume
194
Issue
2
Pages
197-209
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W1996091936
Cited by
185
References
64
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 10 · 2016: 7 · 2015: 11 · 2014: 13 · 2013: 21 · 2012: 18
FWCI
1.99
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
atomoxetine, attention deficit hyperactivity disorder, children and adolescents, ADHD symptom reduction, relapse prevention, adverse events, gastrointestinal adverse effects, oppositional defiant disorder, hyperactive-impulsive subtype, inattentive subtype, quality of life, predictors of treatment response, predictors of adverse events, number needed to treat, number needed to harm, stimulant medication
MeSH terms
Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Propylamines, Quality of Life, Regression Analysis, Sex Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. https://app.cochat.ai/papers/10.1007/s00213-007-0840-x
The paper
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. https://doi.org/10.1007/s00213-007-0840-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.